IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies
have shown that an elevated IL-10 level is an independent risk factor of mortality. It may
also serve as biomarker for very early risk stratification. The aim of this study is to
compare the outcomes for patients with elevated IL-10 levels (≥8 pg/ml) when treated with
standard antibiotic therapy (daptomycin or vancomycin) versus early aggressive therapy
(daptomycin with ceftaroline) for the treatment of MRSaB.